First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer
Breast Cancer
DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel
Clinical tumor regression rate, Chemotherapy combination Gemcitabine with Cisplatin, 4 months
Increasing PFS and OS, Observation after chemotherapy, 5 years and 10 years
Using combination of gemcitabine plus cisplatine as first line treatment patients with locally advanced breast cancer with high TUBB3 expression